Rutland Herald

Cognito Therapeutics and Ochsner Health Launch Brain Health Collaboratory to Advance New Care Models for Alzheimer’s Disease

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...
MassDevice

Cognito Therapeutics has more positive Spectris data

Cognito Therapeutics announced new research highlighting its Spectris therapy's capabilities in Alzheimer's disease.
Business Wire

Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition

Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...
Business Wire

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...